title: [Recommendations of the Infectious Diseases Work Group (GTEI) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically Ill Patients Study Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of influenza A/H1N1 in seriously ill adults admitted to the Intensive Care Unit].
abstract: The diagnosis of influenza A/H1N1 is mainly clinical, particularly during peak or seasonal flu outbreaks. A diagnostic test should be performed in all patients with fever and flu symptoms that require hospitalization. The respiratory sample (nasal or pharyngeal exudate or deeper sample in intubated patients) should be obtained as soon as possible, with the immediate start of empirical antiviral treatment. Molecular methods based on nucleic acid amplification techniques (RT-PCR) are the gold standard for the diagnosis of influenza A/H1N1. Immunochromatographic methods have low sensitivity; a negative result therefore does not rule out active infection. Classical culture is slow and has low sensitivity. Direct immunofluorescence offers a sensitivity of 90%, but requires a sample of high quality. Indirect methods for detecting antibodies are only of epidemiological interest. Patients with A/H1N1 flu may have relative leukopenia and elevated serum levels of LDH, CPK and CRP, but none of these variables are independently associated to the prognosis. However, plasma LDH> 1500 IU/L, and the presence of thrombocytopenia <150 x 10(9)/L, could define a patient population at risk of suffering serious complications. Antiviral administration (oseltamivir) should start early (<48 h from the onset of symptoms), with a dose of 75 mg every 12h, and with a duration of at least 7 days or until clinical improvement is observed. Early antiviral administration is associated to improved survival in critically ill patients. New antiviral drugs, especially those formulated for intravenous administration, may be the best choice in future epidemics. Patients with a high suspicion of influenza A/H1N1 infection must continue with antiviral treatment, regardless of the negative results of initial tests, unless an alternative diagnosis can be established or clinical criteria suggest a low probability of influenza. In patients with influenza A/H1N1 pneumonia, empirical antibiotic therapy should be provided due to the possibility of bacterial coinfection. A beta-lactam plus a macrolide should be administered as soon as possible. The microbiological findings and clinical or laboratory test variables may decide withdrawal or not of antibiotic treatment. Pneumococcal vaccination is recommended as a preventive measure in the population at risk of suffering severe complications. Although the use of moderate- or low-dose corticosteroids has been proposed for the treatment of influenza A/H1N1 pneumonia, the existing scientific evidence is not sufficient to recommend the use of corticosteroids in these patients. The treatment of acute respiratory distress syndrome in patients with influenza A/H1N1 must be based on the use of a protective ventilatory strategy (tidal volume <10 ml / kg and plateau pressure <35 mmHg) and positive end-expiratory pressure set to high patient lung mechanics, combined with the use of prone ventilation, muscle relaxation and recruitment maneuvers. Noninvasive mechanical ventilation cannot be considered a technique of choice in patients with acute respiratory distress syndrome, though it may be useful in experienced centers and in cases of respiratory failure associated with chronic obstructive pulmonary disease exacerbation or heart failure. Extracorporeal membrane oxygenation is a rescue technique in refractory acute respiratory distress syndrome due to influenza A/H1N1 infection. The scientific evidence is weak, however, and extracorporeal membrane oxygenation is not the technique of choice. Extracorporeal membrane oxygenation will be advisable if all other options have failed to improve oxygenation. The centralization of extracorporeal membrane oxygenation in referral hospitals is recommended. Clinical findings show 50-60% survival rates in patients treated with this technique. Cardiovascular complications of influenza A/H1N1 are common. Such problems may appear due to the deterioration of pre-existing cardiomyopathy, myocarditis, ischemic heart disease and right ventricular dysfunction. Early diagnosis and adequate monitoring allow the start of effective treatment, and in severe cases help decide the use of circulatory support systems. Influenza vaccination is recommended for all patients at risk. This indication in turn could be extended to all subjects over 6 months of age, unless contraindicated. Children should receive two doses (one per month). Immunocompromised patients and the population at risk should receive one dose and another dose annually. The frequency of adverse effects of the vaccine against A/H1N1 flu is similar to that of seasonal flu. Chemoprophylaxis must always be considered a supplement to vaccination, and is indicated in people at high risk of complications, as well in healthcare personnel who have been exposed.
authors.affiliation: Servicio de Medicina Intensiva, Hospital Universitario de Tarragona Joan XXIII, IISPV - URV - CIBER Enfermedades Respiratorias, Tarragona, España. ahr1161@yahoo.es
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez
authors.forename: L
authors.initials: L
authors.lastname: Alvarez-Rocha
authors.forename: J M
authors.initials: JM
authors.lastname: Sirvent
authors.forename: R
authors.initials: R
authors.lastname: Zaragoza
authors.forename: M
authors.initials: M
authors.lastname: Nieto
authors.forename: A
authors.initials: A
authors.lastname: Arenzana
authors.forename: P
authors.initials: P
authors.lastname: Luque
authors.forename: L
authors.initials: L
authors.lastname: Socías
authors.forename: M
authors.initials: M
authors.lastname: Martín
authors.forename: D
authors.initials: D
authors.lastname: Navarro
authors.forename: J
authors.initials: J
authors.lastname: Camarena
authors.forename: L
authors.initials: L
authors.lastname: Lorente
authors.forename: S
authors.initials: S
authors.lastname: Trefler
authors.forename: L
authors.initials: L
authors.lastname: Vidaur
authors.forename: J
authors.initials: J
authors.lastname: Solé-Violán
authors.forename: F
authors.initials: F
authors.lastname: Barcenilla
authors.forename: A
authors.initials: A
authors.lastname: Pobo
authors.forename: J
authors.initials: J
authors.lastname: Vallés
authors.forename: C
authors.initials: C
authors.lastname: Ferri
authors.forename: I
authors.initials: I
authors.lastname: Martín-Loeches
authors.forename: E
authors.initials: E
authors.lastname: Díaz
authors.forename: D
authors.initials: D
authors.lastname: López
authors.forename: M J
authors.initials: MJ
authors.lastname: López-Pueyo
authors.forename: F
authors.initials: F
authors.lastname: Gordo
authors.forename: F
authors.initials: F
authors.lastname: del Nogal
authors.forename: A
authors.initials: A
authors.lastname: Marqués
authors.forename: S
authors.initials: S
authors.lastname: Tormo
authors.forename: M P
authors.initials: MP
authors.lastname: Fuset
authors.forename: F
authors.initials: F
authors.lastname: Pérez
authors.forename: J
authors.initials: J
authors.lastname: Bonastre
authors.forename: B
authors.initials: B
authors.lastname: Suberviola
authors.forename: E
authors.initials: E
authors.lastname: Navas
authors.forename: C
authors.initials: C
authors.lastname: León
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000465:Algorithms; D000998:Antiviral Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy; D015199:Extracorporeal Membrane Oxygenation; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007252:Influenza Vaccines / Q000009:adverse effects; D007251:Influenza, Human / Q000150:complications / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy* / Q000821:virology; D007362:Intensive Care Units; D011379:Prognosis; D012121:Respiration, Artificial; D012128:Respiratory Distress Syndrome / Q000188:drug therapy / Q000821:virology; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D000305:Adrenal Cortex Hormones; D000998:Antiviral Agents; D007252:Influenza Vaccines